Matches in SemOpenAlex for { <https://semopenalex.org/work/W3210274624> ?p ?o ?g. }
- W3210274624 endingPage "607" @default.
- W3210274624 startingPage "599" @default.
- W3210274624 abstract "We retrospectively reviewed for 72 relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) patients ineligible for autologous stem-cell transplantation (ASCT) treated between 2004 and 2017, efficacy and safety profile of rituximab (375 mg/m2) in combination with etoposide (300 mg/m2) and ifosfamide (1500 mg/m2) at 2, 3, or 4-week intervals. Median age was 79 years (range, 64-92). The median number of previous line was 1 (range 1-8). Patients received a median of six cycles (1-12). Fourteen patients (19%) presented partial and 14 complete responses (19%). Among the 369 cycles, nine patients developed febrile neutropenia (13%), 14 a grade 3-4 neutropenia (19%), 7 a grade 3-4 thrombocytopenia (10%) without grade 3-4 non-hematological toxicity. With a median follow up of 7.8 months, the median progression-free survival, overall survival, and duration of response were 4.4 months, 9.4 months, and 12 months, respectively. This regimen represents a therapeutic option in R/R DLBCL patients ineligible to ASCT." @default.
- W3210274624 created "2021-11-08" @default.
- W3210274624 creator A5013488023 @default.
- W3210274624 creator A5016764336 @default.
- W3210274624 creator A5017738347 @default.
- W3210274624 creator A5027311948 @default.
- W3210274624 creator A5028004558 @default.
- W3210274624 creator A5028490703 @default.
- W3210274624 creator A5040269772 @default.
- W3210274624 creator A5043831411 @default.
- W3210274624 creator A5050049048 @default.
- W3210274624 creator A5052524269 @default.
- W3210274624 creator A5053019069 @default.
- W3210274624 creator A5068622087 @default.
- W3210274624 creator A5073019715 @default.
- W3210274624 creator A5073288241 @default.
- W3210274624 creator A5074313573 @default.
- W3210274624 creator A5078342005 @default.
- W3210274624 creator A5080009159 @default.
- W3210274624 creator A5083548642 @default.
- W3210274624 creator A5089774334 @default.
- W3210274624 date "2021-10-31" @default.
- W3210274624 modified "2023-09-27" @default.
- W3210274624 title "Rituximab in combination with adapted-dose of ifosfamide and etoposide as salvage treatment in elderly refractory/relapsed diffuse large B-cell lymphoma patients non-candidate for high dose therapy: a retrospective study" @default.
- W3210274624 cites W1499155424 @default.
- W3210274624 cites W1790337787 @default.
- W3210274624 cites W1912693401 @default.
- W3210274624 cites W1971211622 @default.
- W3210274624 cites W1997353354 @default.
- W3210274624 cites W2018713883 @default.
- W3210274624 cites W2058015212 @default.
- W3210274624 cites W2060178495 @default.
- W3210274624 cites W2103563361 @default.
- W3210274624 cites W2117460825 @default.
- W3210274624 cites W2126779872 @default.
- W3210274624 cites W2131424155 @default.
- W3210274624 cites W2133201432 @default.
- W3210274624 cites W2133345449 @default.
- W3210274624 cites W2134646407 @default.
- W3210274624 cites W2150587745 @default.
- W3210274624 cites W2163709153 @default.
- W3210274624 cites W2167571754 @default.
- W3210274624 cites W2342415226 @default.
- W3210274624 cites W2460247604 @default.
- W3210274624 cites W2518731208 @default.
- W3210274624 cites W2605009867 @default.
- W3210274624 cites W2783108477 @default.
- W3210274624 cites W2789889201 @default.
- W3210274624 cites W2795456460 @default.
- W3210274624 cites W2963491578 @default.
- W3210274624 cites W2969766999 @default.
- W3210274624 cites W2972444957 @default.
- W3210274624 cites W2984927918 @default.
- W3210274624 cites W2991110530 @default.
- W3210274624 cites W3024978145 @default.
- W3210274624 cites W3034162969 @default.
- W3210274624 cites W3043369050 @default.
- W3210274624 cites W3047541106 @default.
- W3210274624 cites W3127059308 @default.
- W3210274624 cites W3137124431 @default.
- W3210274624 cites W4230096730 @default.
- W3210274624 doi "https://doi.org/10.1080/10428194.2021.1998483" @default.
- W3210274624 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34720034" @default.
- W3210274624 hasPublicationYear "2021" @default.
- W3210274624 type Work @default.
- W3210274624 sameAs 3210274624 @default.
- W3210274624 citedByCount "0" @default.
- W3210274624 crossrefType "journal-article" @default.
- W3210274624 hasAuthorship W3210274624A5013488023 @default.
- W3210274624 hasAuthorship W3210274624A5016764336 @default.
- W3210274624 hasAuthorship W3210274624A5017738347 @default.
- W3210274624 hasAuthorship W3210274624A5027311948 @default.
- W3210274624 hasAuthorship W3210274624A5028004558 @default.
- W3210274624 hasAuthorship W3210274624A5028490703 @default.
- W3210274624 hasAuthorship W3210274624A5040269772 @default.
- W3210274624 hasAuthorship W3210274624A5043831411 @default.
- W3210274624 hasAuthorship W3210274624A5050049048 @default.
- W3210274624 hasAuthorship W3210274624A5052524269 @default.
- W3210274624 hasAuthorship W3210274624A5053019069 @default.
- W3210274624 hasAuthorship W3210274624A5068622087 @default.
- W3210274624 hasAuthorship W3210274624A5073019715 @default.
- W3210274624 hasAuthorship W3210274624A5073288241 @default.
- W3210274624 hasAuthorship W3210274624A5074313573 @default.
- W3210274624 hasAuthorship W3210274624A5078342005 @default.
- W3210274624 hasAuthorship W3210274624A5080009159 @default.
- W3210274624 hasAuthorship W3210274624A5083548642 @default.
- W3210274624 hasAuthorship W3210274624A5089774334 @default.
- W3210274624 hasConcept C121332964 @default.
- W3210274624 hasConcept C126322002 @default.
- W3210274624 hasConcept C141071460 @default.
- W3210274624 hasConcept C142424586 @default.
- W3210274624 hasConcept C2776694085 @default.
- W3210274624 hasConcept C2777063308 @default.
- W3210274624 hasConcept C2777506904 @default.
- W3210274624 hasConcept C2778119113 @default.
- W3210274624 hasConcept C2778559949 @default.
- W3210274624 hasConcept C2778850193 @default.
- W3210274624 hasConcept C2779050716 @default.